‘Baraclude’ falls, Lipitor and Viread form two-way strong trend

In the outpatient prescription market, ‘Lipitor(Pfizer)’ and ‘Viread(Gilead Sciences Korea)’ formed the 2-way strong trend.

The BMS Korea’s product which had exclusively led the market for the past years, ‘Baraclude’ has constantly fell down without hope, caused by emergence of strong competitors and generics and the patent expiration.

Moreover, the hepatitis C treatment ‘Daklinza(BMS)’ has...